Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases

Author's Avatar
Oct 21, 2019
Article's Main Image

Collaboration aims to explore the use of Cantabio's DJ-1 protein targeting small molecule drug candidates in immune associated diseases at Luxembourg Institute of Health